DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.17
+8.83%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -0.2%
- EBIT
- +2.9%
- EPS
- +40.5%
- Free cash flow
- -9.5%
- Operating cash flow
- -11.7%
Forward estimates
Based on analyst estimates
- Revenue
- +376.5%
- EBITDA
- +9.3%
- EPS
- -43.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -1.0%
- EBIT
- -14.0%
- Net income
- -21.2%
- EPS
- -15.6%
- Free cash flow
- -16.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026